PA
CRBP icon

Pinnacle Associates’s Corbus Pharmaceuticals CRBP Stock Holding History

Pinnacle Associates’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-619
Closed -$2.05K – 777
2022
Q4 		$2.05K Sell
619
-26,956
-98% -$104K ﹤0.01% 758
2022
Q3 		$136K Sell
27,575
-2,759
-9% -$19.5K ﹤0.01% 710
2022
Q2 		$230K Sell
30,334
-162
-0.5% -$1.57K 0.01% 670
2022
Q1 		$486K Sell
30,496
-1,073
-3% -$14.2K 0.01% 567
2021
Q4 		$583K Sell
31,569
-631
-2% -$17.1K 0.01% 532
2021
Q3 		$985K Sell
32,200
-1,074
-3% -$42.4K 0.02% 444
2021
Q2 		$1.83M Buy
33,274
+498
+2% +$27.6K 0.03% 347
2021
Q1 		$1.94M Buy
32,776
+1,373
+4% +$90.3K 0.04% 327
2020
Q4 		$1.18M Sell
31,403
-7,378
-19% -$276K 0.02% 376
2020
Q3 		$2.09M Sell
38,781
-1,366
-3% -$247K 0.05% 270
2020
Q2 		$10.1M Sell
40,147
-646
-2% -$131K 0.25% 110
2020
Q1 		$6.41M Buy
+40,793
New +$6.9M 0.19% 130

Other funds holding CRBP

IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Pinnacle Associates's CRBP Position: Q1 2023 in Review

Pinnacle Associates sold out of Corbus Pharmaceuticals (CRBP) in Q1 2023, closing a stake of 619 shares — an estimated $2.05K sold.

Pinnacle Associates first reported a position in CRBP in Q1 2020 and held it in 12 quarters. The position peaked at $10.1M in Q2 2020. 30 funds tracked by Wall St. Rank hold CRBP as of Q1 2023.

  • Pinnacle Associates reported no remaining Corbus Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Pinnacle Associates sold 619 Corbus Pharmaceuticals shares in Q1 2023, an estimated $2.05K.
  • Pinnacle Associates first reported a position in Corbus Pharmaceuticals in Q1 2020 and held it in 12 quarters.
  • Pinnacle Associates's Corbus Pharmaceuticals position peaked at $10.1M in Q2 2020.
  • 30 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2023.

Based on Pinnacle Associates's 13F filing for Q1 2023, filed 5 May 2023.